McKesson Reports Strong FY26 Results, Authorizes $7.7B Share Repurchase, and Details Medical-Surgical Segment Separation
MCK sits 17% above its 52-week low of $637 on elevated volume (2.4× avg).
Summary
McKesson reported robust fiscal year 2026 financial results, including double-digit revenue and EPS growth, alongside an expanded $7.7 billion share repurchase authorization and detailed plans for the strategic separation of its Medical-Surgical Solutions segment with a $1.25 billion investment from Apollo.
Key Events · Earnings and Guidance · MCK
-
Strong Fiscal Year 2026 Financial Performance
McKesson reported a 12% increase in revenues to $403.43 billion, a 45% rise in net income attributable to McKesson Corporation to $4.76 billion, and a 49% surge in diluted EPS to $38.38 for the fiscal year ended March 31, 2026, confirming robust growth across its segments.
-
Expanded Share Repurchase Program
The Board authorized an additional $5.0 billion for common stock repurchases on April 29, 2026, bringing the total authorization to $7.7 billion. The company repurchased $4.8 billion in common stock during fiscal 2026.
-
Strategic Medical-Surgical Segment Separation
McKesson detailed its intention to separate the Medical-Surgical Solutions segment into an independent company. As part of this strategy, Apollo Funds will acquire a 13% minority ownership interest for approximately $1.25 billion in convertible preferred equity.
-
Significant Acquisitions and Divestitures
The company completed the acquisition of an 80% controlling interest in PRISM Vision for $875 million and a 70% controlling interest in Core Ventures for $2.5 billion, expanding its Oncology & Multispecialty segment. It also completed the sale of its Norwegian operations for $821 million, resulting in a $480 million net gain.
Analysis · MCK · Trade & Services
This annual 10-K filing provides comprehensive audited financial results for fiscal year 2026, confirming strong performance with significant revenue and earnings growth. It details a substantial increase in the share repurchase authorization to $7.7 billion, signaling a strong commitment to capital return. Crucially, the filing elaborates on the strategic separation of the Medical-Surgical Solutions segment, including a $1.25 billion investment from Apollo Funds for a 13% minority stake, a move expected to unlock significant value. While some of this information was previously summarized in an 8-K, the 10-K provides the full audited financial context and granular details, making it highly important for investors to understand the company's financial health, strategic direction, and capital allocation plans.
At the time of this filing, MCK was trading at $745.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $92.4B. The 52-week trading range was $637.00 to $999.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.